ORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) — by way of InvestorWire — Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that it has filed a provisional patent application (PPA) with the United States Patent and Trademark Office (USPTO) for novel methods of drug-assisted psychotherapy.

Drug-assisted psychotherapy combines drug and psychological treatments to leverage the benefits of each for a superior outcome. Most notably, drug-assisted therapy often improves the patient-therapist relationship and increases flexibility in the patient’s mind, allowing patients to discover and incorporate new ways of addressing their conditions.

One of the complications of drug-assisted therapy is that continuous exposure to some drugs, i.e., MDMA, can result in patients developing tolerance to the drug, thereby hampering therapy. The underlying invention of Clearmind’s PPA is a method for treating subjects who are resistant to MDMA-assisted psychotherapy or those for whom it has become ineffective, undesirable or inappropriate.

The PPA, which was filed on Friday, Oct. 8, 2021, establishes an effective filing date for protection of any invention described within it and establishes a date as prior art against later-filed applications.

Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented: “This filing is another marker in our commitment to build value by establishing a best-in-class IP portfolio to include novel molecules, delivery mechanisms, processes and protocols. These discoveries reflect the dedication, innovation and creativity at the heart of our research and development team and position us to pursue the substantial market opportunity in the field of psychedelic-based medicine.”

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech firm targeted on the invention and improvement of novel psychedelic-derived therapeutics to remedy widespread and underserved well being issues, together with alcohol use dysfunction. Its main goal is to analysis and develop psychedelic-based compounds and try to commercialize them as regulated medicines, meals or dietary supplements.

The Company’s mental portfolio at the moment consists of two further patent households. The first, “Binge Behavior Regulators,” has been granted within the U.S., Europe, China and India, with pending divisional purposes in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been authorised for a European patent, with pending purposes within the U.S., China and India. The Company intends to search further patents for its compounds each time warranted and can stay opportunistic concerning the acquisition of further mental property to construct its portfolio.

Shares of Clearmind are listed for buying and selling on the Canadian Securities Exchange beneath the image “CMND” and the Frankfurt Stock Exchange beneath the image “CWY0.”

Clearmind Medicine will host ‘Psychedelics for Alcoholism,’ a free, dwell digital occasion highlighting new potential remedies for alcohol use dysfunction and binge consuming, on Oct. 20, 2021. Register here

For additional info, please contact:

Investor Relations,
Email: make investments@clearmindmedicine.com
Telephone: (778) 400-5347

General Inquiries,


This information launch might include forward-looking statements and knowledge primarily based on present expectations. These statements shouldn’t be learn as ensures of future efficiency or outcomes. Such statements contain recognized and unknown dangers, uncertainties and different components that will trigger precise outcomes, efficiency or achievements to be materially completely different from these implied by such statements. Such statements embody submission of the related documentation throughout the required timeframe to the satisfaction of the related regulators and elevating enough financing to full the Company’s enterprise technique. There isn’t any certainty that any of these occasions will happen. Although such statements are primarily based on administration’s cheap assumptions, there may be no assurance that such assumptions will show to be appropriate. The Company assumes no duty to replace or revise them to mirror new occasions or circumstances.

Investing into early-stage corporations inherently carries a excessive diploma of danger, and funding into securities of the Company shall be thought of extremely speculative.

This press launch shall not represent a proposal to promote or the solicitation of a proposal to purchase, nor shall there be any sale of, the securities in any province during which such provide, solicitation or sale can be illegal. The securities issued, or to be issued, beneath the Private Placement haven’t been, and won’t be, registered beneath the United States Securities Act of 1933, as amended, and is probably not provided or bought within the United States absent registration or an relevant exemption from registration necessities.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that time period is outlined within the insurance policies of the CSE) accepts duty for the adequacy or accuracy of this launch.

Source link